CL2013000580A1 - Metodo de regeneracion o reparacion muscular que comprende administrar un antagonista del receptor de acido retinoico gama (rary); metodo para la induccion o estimulacion de diferenciacion miogenica de celulas madre; composicion que comprende celulas madre mesenquimales; composicion farmaceutica; kit. - Google Patents

Metodo de regeneracion o reparacion muscular que comprende administrar un antagonista del receptor de acido retinoico gama (rary); metodo para la induccion o estimulacion de diferenciacion miogenica de celulas madre; composicion que comprende celulas madre mesenquimales; composicion farmaceutica; kit.

Info

Publication number
CL2013000580A1
CL2013000580A1 CL2013000580A CL2013000580A CL2013000580A1 CL 2013000580 A1 CL2013000580 A1 CL 2013000580A1 CL 2013000580 A CL2013000580 A CL 2013000580A CL 2013000580 A CL2013000580 A CL 2013000580A CL 2013000580 A1 CL2013000580 A1 CL 2013000580A1
Authority
CL
Chile
Prior art keywords
stem cells
composition
rary
stimulation
administering
Prior art date
Application number
CL2013000580A
Other languages
English (en)
Inventor
Masahiro Iwamoto
Maurizio Pacifici
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45773490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000580(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of CL2013000580A1 publication Critical patent/CL2013000580A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Método de regeneración o reparación muscular que comprende administrar un antagonista del receptor de ácido retinoico gama (RARY); método para la inducción o estimulación de diferenciación miogénica de células madre; composición que comprende células madre mesenquimales; composición farmacéutica; kit.
CL2013000580A 2010-09-01 2013-02-28 Metodo de regeneracion o reparacion muscular que comprende administrar un antagonista del receptor de acido retinoico gama (rary); metodo para la induccion o estimulacion de diferenciacion miogenica de celulas madre; composicion que comprende celulas madre mesenquimales; composicion farmaceutica; kit. CL2013000580A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37899610P 2010-09-01 2010-09-01

Publications (1)

Publication Number Publication Date
CL2013000580A1 true CL2013000580A1 (es) 2013-07-12

Family

ID=45773490

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000580A CL2013000580A1 (es) 2010-09-01 2013-02-28 Metodo de regeneracion o reparacion muscular que comprende administrar un antagonista del receptor de acido retinoico gama (rary); metodo para la induccion o estimulacion de diferenciacion miogenica de celulas madre; composicion que comprende celulas madre mesenquimales; composicion farmaceutica; kit.

Country Status (20)

Country Link
US (6) US9789074B2 (es)
EP (3) EP3721880B1 (es)
JP (1) JP5986570B2 (es)
CN (2) CN111773213B (es)
AU (1) AU2011296080B2 (es)
BR (1) BR112013004685B1 (es)
CA (1) CA2809374C (es)
CL (1) CL2013000580A1 (es)
CO (1) CO6680694A2 (es)
DK (2) DK2613776T3 (es)
EA (1) EA026251B1 (es)
ES (3) ES2912593T3 (es)
HU (2) HUE051664T2 (es)
IL (1) IL224973B (es)
MX (2) MX361414B (es)
NZ (1) NZ607547A (es)
PL (2) PL3721880T3 (es)
PT (1) PT2613776T (es)
WO (1) WO2012030919A2 (es)
ZA (1) ZA201301536B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111773213B (zh) 2010-09-01 2023-02-24 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
US9782417B2 (en) 2011-06-16 2017-10-10 Presidents And Fellows Of Harvard College Methods of increasing satellite cell proliferation with kinase inhibitors
US11026952B2 (en) 2011-06-16 2021-06-08 President And Fellows Of Harvard College Small molecules for mouse satellite cell proliferation
US11963964B2 (en) 2011-06-16 2024-04-23 President And Fellows Of Harvard College Small molecules for mouse satellite cell proliferation
WO2014073209A1 (ja) * 2012-11-08 2014-05-15 国立大学法人山口大学 角結膜障害の治療剤
EP2943564B1 (en) * 2013-01-09 2026-03-25 International Stem Cell Corporation Sl327 for use in skin regeneration
US10702502B2 (en) * 2013-05-22 2020-07-07 Yamaguchi University Inhibitor for retinochoroidal disorders
EP3152190B1 (en) 2014-06-04 2024-07-31 Haro Pharmaceutical Inc. 18-20 member bi-polycyclic compounds
US9784665B1 (en) * 2014-12-29 2017-10-10 Flagship Biosciences, Inc. Methods for quantitative assessment of muscle fibers in muscular dystrophy
EP3291693A4 (en) 2015-05-06 2019-04-03 University of Southern California FASTENIMITIER AND IMPROVING DIET FOR THE TREATMENT OF HYPERTENSION AND LIPID DISORDER
EP3091084A1 (en) * 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation
CN109069516A (zh) * 2016-02-01 2018-12-21 哈佛学院校长同事会 用于小鼠卫星细胞增殖的小分子
ES2963348T3 (es) 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
JP7018957B2 (ja) 2016-11-16 2022-02-14 クレメンティア ファーマシューティカルズ インコーポレイテッド 多発性骨軟骨腫（ｍｏ）を処置するための方法
CA3019069A1 (en) * 2018-04-02 2019-10-02 Hubit Genomix, Inc. Prophylactic and/or therapeutic drug for diabetic nephropathy
US11135236B2 (en) * 2018-04-10 2021-10-05 Northwestern University Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity
GB201907647D0 (en) * 2019-05-30 2019-07-17 King S College London Therapeutic methods
FR3112684B1 (fr) * 2020-07-24 2022-08-12 Univ Grenoble Alpes Composés pour le traitement de l’hémophilie
CN116891497B (zh) * 2022-04-02 2025-12-16 上海旭成医药科技有限公司 视黄酸受体激动剂、其制备方法、中间体、药物组合物和应用
WO2023241717A1 (zh) * 2022-06-16 2023-12-21 中国科学院动物研究所 促进哺乳动物器官再生修复的物质及其应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS60500864A (ja) 1983-02-04 1985-06-06 ワドリ、テクナラジズ、インコーパレイティド 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
JPS6253981A (ja) 1985-09-02 1987-03-09 Koichi Shiyudo 新規安息香酸誘導体
AU618590B2 (en) 1988-04-11 1992-01-02 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
CA2129773C (en) 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5408002A (en) 1993-09-09 1995-04-18 Minnesota Mining And Manufacturing Company Azlactone-functional polymer blends, articles produced therefrom and methods for preparing both
US5498795A (en) 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5807900A (en) 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
US5726191A (en) 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
AU7481098A (en) * 1997-05-13 1998-12-08 Case Western Reserve University Osteoarthritis cartilage regeneration using human mesenchymal stem ce lls
US7514074B2 (en) * 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
WO1999061587A1 (en) 1998-05-29 1999-12-02 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
CA2344919A1 (en) 1998-09-24 2000-03-30 Bristol-Myers Squibb Company Active enantiomer of rar.gamma.-specific agonist
JO2178B1 (en) 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of emphysema using rar selective retinoid antagonists
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
CA2402413A1 (en) 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
EP1285057B1 (en) 2000-04-28 2006-05-31 Children's Medical Center Corporation Isolation of mesenchymal stem cells and use thereof
WO2002028810A2 (en) 2000-10-02 2002-04-11 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
BR0212583A (pt) 2001-09-18 2004-10-13 Hoffmann La Roche Agonistas i para retinóides de alquil uréia
AU2002340886B2 (en) 2001-09-18 2008-01-31 F. Hoffmann-La Roche Ag Substituted urea retinoid agonists II
AUPR892501A0 (en) * 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US7592174B2 (en) 2002-05-31 2009-09-22 The Board Of Trustees Of The Leland Stanford Junior University Isolation of mesenchymal stem cells
MXPA04011815A (es) * 2002-06-04 2005-03-31 Galderma Res & Dev Nuevos ligandos inhibidores de los receptores rars, su procedimiento de preparacion y su uso en medicina humana asi como en cosmetica.
DE60326453D1 (de) * 2002-07-03 2009-04-16 Ct Cardiologico Monzino S P A Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
EP1551955A4 (en) 2002-07-16 2006-11-29 Yissum Res Dev Co METHOD FOR IMPLANTING MESENCHYMAL STEM CELLS FOR TISSUE PAIRING AND FORMATION
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
JP2005206544A (ja) * 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
FR2894959B1 (fr) 2005-12-15 2008-02-29 Galderma Res & Dev Derives biphenyliques agonistes selectifs du recepteur rar-gamma
FR2894960B1 (fr) 2005-12-15 2008-02-29 Galderma Res & Dev Derives biphenyliques agonistes selectifs du recepteurs rar-gamma
US20070213308A1 (en) 2006-01-26 2007-09-13 Lessem Jan N Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
ES2395401T3 (es) * 2006-03-23 2013-02-12 Tmrc Co., Ltd. kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer
CA2647275A1 (en) 2006-03-31 2007-10-11 F. Hoffmann-La Roche Ag Process for preparing retinoid compounds
CN101472572B (zh) 2006-05-16 2012-10-10 Io治疗有限责任公司 Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
EP2379174A4 (en) 2008-12-18 2012-11-14 Astrazeneca Ab PHARMACEUTICAL PRODUCT USING A P38 KINASE INHIBITOR AND A SECOND ACTIVE SUBSTANCE
WO2010088735A1 (en) * 2009-02-05 2010-08-12 Regenertech Pty Ltd Method of producing progenitor cells from differentiated cells
US20120277156A1 (en) 2009-07-21 2012-11-01 University Of Washington Trhough It's Center For Commercialization Inhibition of pathological bone formation
UA50725U (ru) * 2009-12-01 2010-06-25 Институт Нейрохирургии Им. Акад. А.П. Ромоданова Амн Украины Способ лечения больных с прогрессирующей мышечной дистрофией трансплантацией миобластов эмбриона человека
CN111773213B (zh) 2010-09-01 2023-02-24 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2013006372A1 (en) 2011-07-01 2013-01-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating pathologic heterotopic ossification
AU2013222345B2 (en) 2012-02-22 2017-09-07 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as TNAP inhibitors
JP6430383B2 (ja) 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害剤としての縮合複素環化合物
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
US10702502B2 (en) 2013-05-22 2020-07-07 Yamaguchi University Inhibitor for retinochoroidal disorders
EP3201187A4 (en) 2014-10-01 2018-04-11 The Brigham and Women's Hospital, Inc. Compositions and methods for inhibiting bmp
US20180311356A1 (en) 2015-10-19 2018-11-01 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
WO2017112431A1 (en) 2015-12-24 2017-06-29 The Regents Of The University Of Michigan Method of treating heterotopic ossification
ES2963348T3 (es) 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
JP6630255B2 (ja) 2016-09-30 2020-01-15 株式会社沖データ 画像形成装置及び通信システム

Also Published As

Publication number Publication date
US9314439B2 (en) 2016-04-19
US9789074B2 (en) 2017-10-17
EA026251B1 (ru) 2017-03-31
EP4066826A1 (en) 2022-10-05
EP4066826B1 (en) 2024-03-06
MX361414B (es) 2018-12-05
HUE051664T2 (hu) 2021-03-29
EP4066826C0 (en) 2024-03-06
CO6680694A2 (es) 2013-05-31
EP3721880B1 (en) 2022-02-02
US20140363402A1 (en) 2014-12-11
DK3721880T3 (da) 2022-05-09
PL3721880T3 (pl) 2022-05-23
EP2613776A4 (en) 2014-03-12
ES2823234T3 (es) 2021-05-06
US20200069620A1 (en) 2020-03-05
DK2613776T3 (da) 2020-10-19
US12023312B2 (en) 2024-07-02
ES2912593T3 (es) 2022-05-26
WO2012030919A3 (en) 2012-07-05
AU2011296080A1 (en) 2013-03-14
EP2613776A2 (en) 2013-07-17
US20230201146A1 (en) 2023-06-29
EP3721880A1 (en) 2020-10-14
CA2809374A1 (en) 2012-03-08
CN111773213A (zh) 2020-10-16
US20250108022A1 (en) 2025-04-03
US20180000762A1 (en) 2018-01-04
CN111773213B (zh) 2023-02-24
CN103200937A (zh) 2013-07-10
ES2975123T3 (es) 2024-07-03
BR112013004685A2 (pt) 2019-04-24
EA201370051A1 (ru) 2014-03-31
MX2013002275A (es) 2013-05-22
JP2013536855A (ja) 2013-09-26
ZA201301536B (en) 2015-06-24
CN103200937B (zh) 2020-07-03
EP2613776B1 (en) 2020-07-29
PT2613776T (pt) 2020-10-21
HUE059024T2 (hu) 2022-10-28
US10292954B2 (en) 2019-05-21
WO2012030919A2 (en) 2012-03-08
BR112013004685B1 (pt) 2021-09-21
AU2011296080B2 (en) 2014-12-04
IL224973B (en) 2018-06-28
NZ607547A (en) 2015-06-26
US20140303223A1 (en) 2014-10-09
JP5986570B2 (ja) 2016-09-06
PL2613776T3 (pl) 2021-01-11
CA2809374C (en) 2021-02-23
MX2018015032A (es) 2021-12-08
US11433039B2 (en) 2022-09-06

Similar Documents

Publication Publication Date Title
JOP20210064B1 (ar) طريقة لانتاج ( z)-ألفا-فلورو-بيتا-أمينو-أكريل الدهيدات مستبدلة
DOP2012000105A (es) Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetes
BR112013004685A2 (pt) composição e método para reparação e regeneração muscular
CR20150370A (es) Compuestos antivirales
MX359291B (es) Adn libre de celulas como objetivo terapeutico para la infertilidad femenina y marcador de diagnostico.
PH12014502217A1 (en) Methods for improving diaphragm function
EA201290988A1 (ru) Стереоселективный синтез фосфорсодержащих активных соединений
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
CL2014003026A1 (es) Compuestos heterobiciclicos derivados de imidazopiridina, imidazopirazina, triazolopiridina y triazolopirazina, inhibidores de la actividad nampt; composicion farmaceutica que los comprende; y metodo para tratar trastornos inflamatorios y de reparacion de tejido, dermatosis y enfermadades autoinmunes.
NZ624726A (en) Methods for treating gout flares
EA201390948A1 (ru) Лечение боли, обусловленной смещением базального слоя эндометрия
MX339793B (es) Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.
MX358991B (es) Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia.
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
PH12012502525A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
WO2012142409A3 (en) Diagnostic markers and therapeutic targets of kawasaki disease
MX343059B (es) Derivados de desmetil-estradiol sustituido en 6 como agonistas de er-beta selectivos.
UY34407A (es) Nuevos moduladores de trpv3
MX2013001612A (es) Moduladores de trpv3 novedosos.
MX2015001488A (es) Tratamiento de la inflamacion utilizando serelaxina.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
UY33332A (es) Compuestos de triazol como inhibidores de ksp
MX2015009606A (es) Uso de un péptido natriurético, un péptido diurético o un péptido vasodilatador en la elaboración de un medicamento para tratar una condición cardiovascular.